Sun Pharma’s disciplined mergers and acquisitions strategy, as emphasized by Shanghvi

Sun Pharma’s Chairman, Dilip Shanghvi, emphasized the company’s commitment to a disciplined approach to acquisitions to ensure organic growth and maintain shareholder value. According to Shanghvi, the Mumbai-based pharmaceutical giant is also exploring opportunities in the biosimilar segment.

When asked about the company’s merger and acquisition strategy during an analyst call, Shanghvi highlighted the significance of the US market for Sun Pharma, particularly in the realm of innovative medicines. He expressed the company’s interest in distributing innovative medications globally. For emerging markets, Shanghvi mentioned a focus on smaller acquisitions to integrate them seamlessly with their existing operations and achieve scale.

Shanghvi reiterated Sun Pharma’s consistent stance on maintaining discipline in acquisitions to safeguard shareholder interests. He underscored the importance of organic growth and being an appealing investment option for shareholders. Acquisitions, as Shanghvi pointed out, should align with the company’s long-term strategic goals and be managed effectively without compromising growth. He also mentioned the company’s willingness to leverage debt for strategic acquisitions.

Regarding biosimilars, Shanghvi indicated that Sun Pharma is reassessing its approach by considering factors such as manufacturing setup, investment requirements, development costs, and return on investment timelines. This comprehensive evaluation will culminate in well-informed decisions by the company.

The Indian government’s proposed budget allocation of Rs 10,000 crore to boost the country’s biopharmaceutical sector over the next five years was highlighted by Shanghvi as a significant step towards fostering health innovation in India. This investment is poised to shape the future of healthcare and innovation in the nation.

Overall, Sun Pharma’s prudent approach to acquisitions, coupled with its focus on innovation and global growth, underscores the company’s commitment to sustainable growth and shareholder value. Through strategic decisions and a forward-looking mindset, Sun Pharma continues to make strides in the pharmaceutical industry while adapting to changing market dynamics and opportunities.